Evidence map›Paper›PMID 34956317›Full record

ReviewFrontiers in genetics2021

Hereditary Multiple Exostoses-A Review of the Molecular Background, Diagnostics, and Potential Therapeutic Strategies.

Ewelina Bukowska-Olech, Wiktoria Trzebiatowska, Wiktor Czech, Olga Drzymała, Piotr Frąk, Franciszek Klarowski, Piotr Kłusek, Anna Szwajkowska, Aleksander Jamsheer

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 69 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. What's new in pediatric bone sarcomas and benign bone tumors.Journal of children's orthopaedics · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Mucin-typebioRxiv : the preprint server for biology · 2025
    Article
  15. Review
  16. Management of Lower Extremity Deformity in Children with Hereditary Multiple Exostoses.Journal of the Pediatric Orthopaedic Society of North America · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ewelina Bukowska-OlechDepartment of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland.
Wiktoria TrzebiatowskaMedical Student, Poznan University of Medical Sciences, Poznan, Poland.
Wiktor CzechMedical Student, Poznan University of Medical Sciences, Poznan, Poland.
Olga DrzymałaMedical Student, Poznan University of Medical Sciences, Poznan, Poland.
Piotr FrąkMedical Student, Poznan University of Medical Sciences, Poznan, Poland.
Franciszek KlarowskiMedical Student, Poznan University of Medical Sciences, Poznan, Poland.
Piotr KłusekMedical Student, Poznan University of Medical Sciences, Poznan, Poland.
Anna SzwajkowskaMedical Student, Poznan University of Medical Sciences, Poznan, Poland.
Aleksander JamsheerDepartment of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland.
Poznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary multiple exostoses (HMEs) syndrome, also known as multiple osteochondromas, represents a rare and severe human skeletal disorder. The disease is characterized by multiple benign cartilage-capped bony outgrowths, termed exostoses or osteochondromas, that locate most commonly in the juxta-epiphyseal portions of long bones. Affected individuals usually complain of persistent pain caused by the pressure on neighboring tissues, disturbance of blood circulation, or rarely by spinal cord compression. However, the most severe complication of this condition is malignant transformation into chondrosarcoma, occurring in up to 3.9% of HMEs patients. The disease results mainly from heterozygous loss-of-function alterations in the

Indexed as

diaphyseal aclasisEXT1 geneEXT2 genehereditary multiple exostoses (HME)HME diagnosticsHME molecular backroundHME therapeutic strategiesmultiple osteochondromas (MO)

Identifiers

PMID34956317
PMCPMC8704583
OpenAlexW4200132536

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.